GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as ...

PEPFAR, a global program to combat AIDS, faces an existential threat due to partisan politics, but Congress has an opportunity to reform the program and ensure its continued success.

Adults living with HIV in Malawi are more than twice as likely to also have dementia compared to those without HIV, according ...

Adults living with HIV in Malawi are more than twice as likely to also have dementia compared to those without HIV, according ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year.

New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Researchers from Imperial College London, working with the University of Oxford and Rockefeller University, have shown ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...